摘要
目的观察渴络欣联合厄贝沙坦治疗早期(Ⅲ期)糖尿病肾病患者蛋白尿的疗效。方法将102例Ⅲ期糖尿病肾病患者随机分为试验组54例和对照组48例。试验组予以渴络欣联合厄贝沙坦治疗,对照组单用厄贝沙坦治疗。2组治疗8周后检测并比较24h尿蛋白定量及血肌酐、血清白蛋白水平。结果 2组治疗后24h尿蛋白定量低于治疗前,血清白蛋白水平高于治疗前,且试验组24小时尿蛋白定量低于对照组,差异具有统计学意义(P<0.05)。2组均未出现明显不良反应。结论渴络欣联合厄贝沙坦治疗早期(Ⅲ期)糖尿病肾病安全、有效,在减少尿蛋白方面效果优于单用厄贝沙坦。
Objective To observe the clinical efficacy of keluoxin combined Irbesartan in proteinuria of stage III of diabetic nephropathy. Methods 102 cases of patients with stage 19 diabetic nephropathy were randomly divided into experi- mental group （54 cases） and control group（48 cases）. Experimental group was treated with Keluoxin combined with Irbesar- tan, Control group was treated by single Irbesartan. 8 weeks after treatment, compared the 24h urine protein and serum creati- nine , serum albumin levels of 2 groups. Results Before treatment,the level of 24h urine protein, serum creatinine and serum albumin were no statistically significant （P 〉 0.05 ）. 8 weeks after treatment, the 24h urine protein of 2 groups were lower than that before treatment, the difference was statistically significant （P 〈 0.05）. Conclusion Treating stage 19 diabetic nephropa- thy with keluoxin combined Irbesartan is safe, and has better effectiveness than Irbesartan single. The 2 drugs play a synergistic role in the treatment of stage 111 diabetic nephropathy.
出处
《临床合理用药杂志》
2013年第34期20-21,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
渴络欣
厄贝沙坦
糖尿病肾病
蛋白尿
Keluoxin
Irbesartan
Diabetic nephropathy
Proteinuria
